Company Highlights

June 16, 2026

Integrated Nanotherapeutics is featured by Pacific Economic Development Canada (PacifiCan) with an exclusive interview with our CEO, Chris Tam.

June 10, 2026

Integrated Nanotherapeutics will be partnering at BIO International 2026, June 22-25, in San Diego, CA.

May 6, 2026

Integrated Nanotherapeutics will be exhibiting at Web Summit 2026, May 11-14, in Vancouver, BC.

Apr 20, 2026

Integrated Nanotherapeutics will be speaking at the 21st Immunology of Diabetes Society Congress & Australian Islet Study Group Meeting (IDS) 2026, Apr 20-24, in Brisbane, Australia.

Mar 18, 2026

Integrated Nanotherapeutics Secures Genome Canada GAPP Funding to Advance Multi-Cargo mRNA/LNP Therapy for Type 1 Diabetes Toward the Clinic.

Mar 3, 2026

Integrated Nanotherapeutics will be speaking at the 9th Antigen-Specific Immune Tolerance Summit (ASIT) 2026 Annual Meeting, Mar 3-6, in Boston.

Jan 12, 2026

Integrated Nanotherapeutics will be attending Biotech Showcase 2026 during JPM Week, Jan 13 – 15, in San Francisco.

Feb 25, 2025

Integrated Nanotherapeutics will be speaking at the 8th Antigen-Specific Immune Tolerance Summit (ASIT) 2025, Feb 25 – 27, in Boston.

Jan 13, 2025

Integrated Nanotherapeutics will be attending Biotech Showcase 2025 during JPM Week, Jan 13 – 15, in San Francisco.

Sep 9, 2024

Integrated Nanotherapeutics and Breakthrough T1D Collaborate to Advance Development of an Immune Tolerizing Therapeutic to Treat Type 1 Diabetes.

Jun 11, 2024

Integrated Nanotherapeutics is presenting T1D preclinical data at the Federation of Clinical Immunology Societies (FOCIS) 2024 Annual Meeting, June 18 – 21, in San Francisco.

June 18, 2026

Integrated Nanotherapeutics welcomes Dr. Carmella Evans-Molina to the Scientific Advisory Board.

June 22, 2026

Integrated Nanotherapeutics was invited to exhibit at World Health Expo (WHX) Osaka 2026, July 2-4, in Osaka, Japan.